Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 8/20 | 0.39 |
| ▸ | LATS1 | O95835 | 6/20 | 0.39 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044584 | 0.89 | USP1 (0.42) | FGFR3KDRGABRA5JAK3JAK2 | |
| SCHEMBL10044596 | 0.89 | USP1 (0.42) | FGFR3KDRGABRA5JAK3JAK2 | |
| SCHEMBL10044581 | 0.87 | FGFR3 (0.41) | FGFR3KDRTBK1 | |
| SCHEMBL10044583 | 0.86 | FGFR3 (0.39) | FGFR3KDRTRPV3TBK1 | |
| SCHEMBL10044616 | 0.86 | FGFR3 (0.39) | FGFR3KDRTRPV3TBK1 | |
| SCHEMBL10044586 | 0.85 | PI4KB (0.41) | FGFR3KDRTBK1 | |
| SCHEMBL10044595 | 0.84 | PTGES (0.40) | FGFR3KDRGABRA5 | |
| SCHEMBL10044594 | 0.82 | JAK3 (0.44) | FGFR3KDRJAK3JAK2 | |
| SCHEMBL10044587 | 0.82 | JAK3 (0.43) | FGFR3KDRJAK3JAK2 | |
| SCHEMBL10044609 | 0.81 | JAK3 (0.42) | FGFR3KDRJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | FGFR3 574/4885LATS1 599/4885LATS2 655/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | FGFR3 574/4885LATS1 599/4885LATS2 655/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | FGFR3 574/4885LATS1 599/4885LATS2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.